Targeting Cancer Stemness in the Clinic: From Hype to Hope.

Tumors are composed of non-homogeneous cell populations exhibiting varying degrees of genetic and functional heterogeneity. Cancer stem cells (CSCs) are capable of sustaining tumors by manipulating genetic and non-genetic factors to metastasize, resist treatment, and maintain the tumor microenvironment. Understanding the key traits and mechanisms of CSC survival provides opportunities to improve patient outcomes via improved prognostic models and therapeutics. Here, we review the clinical significance of CSCs and results of potential CSC-targeting therapies in various cancers. We discuss barriers to translating cues from pre-clinical models into clinical applications and propose new strategies for rational design of future anti-CSC trials.

[1]  Andrew M. K. Brown,et al.  Variable Clonal Repopulation Dynamics Influence Chemotherapy Response in Colorectal Cancer , 2013, Science.

[2]  Aleksandar Sekulic,et al.  Efficacy and safety of vismodegib in advanced basal-cell carcinoma. , 2012, The New England journal of medicine.

[3]  Lin Zhang,et al.  Distinct Expression Levels and Patterns of Stem Cell Marker, Aldehyde Dehydrogenase Isoform 1 (ALDH1), in Human Epithelial Cancers , 2010, PloS one.

[4]  Michael C. Rusch,et al.  Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Visvader,et al.  Cancer stem cells: current status and evolving complexities. , 2012, Cell stem cell.

[6]  Z. Werb,et al.  The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? , 2015, Cell stem cell.

[7]  P. Paschka,et al.  Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia , 2016, Oncotarget.

[8]  Justin C. Grindley,et al.  Tumour-initiating cells: challenges and opportunities for anticancer drug discovery , 2009, Nature Reviews Drug Discovery.

[9]  Alexander Staab,et al.  A Phase I Dose Escalation Study with Anti-CD44v6 Bivatuzumab Mertansine in Patients with Incurable Squamous Cell Carcinoma of the Head and Neck or Esophagus , 2006, Clinical Cancer Research.

[10]  T. Yeatman,et al.  A phase II study of RO4929097 in metastatic colorectal cancer. , 2012, European journal of cancer.

[11]  R. Houot,et al.  Inhibition of Hedgehog signaling for the treatment of lymphoma and CLL: a phase II study from the LYSA. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  A. Lánczky,et al.  Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer , 2013, Proceedings of the National Academy of Sciences.

[13]  J. Berlin,et al.  A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer , 2012, Clinical Cancer Research.

[14]  P. Valent,et al.  Cancer stem cells in basic science and in translational oncology: can we translate into clinical application? , 2015, Journal of Hematology & Oncology.

[15]  Mithat Gonen,et al.  Long‐Term Follow‐up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia , 2018, The New England journal of medicine.

[16]  I. Weissman,et al.  The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications. , 2012, Current opinion in immunology.

[17]  J. Rich.  Cancer stem cells: understanding tumor hierarchy and heterogeneity , 2016, Medicine.

[18]  M. Konopleva,et al.  Mobilization and elimination of FLT3-ITD+ acute myelogenous leukemia (AML) stem/progenitor cells by plerixafor, G-CSF, and sorafenib: Phase I trial results in relapsed/refractory AML patients. , 2014 .

[19]  J. Aster,et al.  A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Gary D Bader,et al.  miR-126 Regulates Distinct Self-Renewal Outcomes in Normal and Malignant Hematopoietic Stem Cells , 2016, Cancer cell.

[21]  J. Lathia,et al.  Reporter Systems to Study Cancer Stem Cells. , 2016, Methods in molecular biology.

[22]  K. Nakayama,et al.  To wake up cancer stem cells, or to let them sleep, that is the question , 2016, Cancer science.

[23]  William W Harless.  Cancer treatments transform residual cancer cell phenotype , 2011, Cancer Cell International.

[24]  R. Majeti,et al.  Biology and relevance of human acute myeloid leukemia stem cells. , 2017, Blood.

[25]  Howard Y. Chang,et al.  Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells. , 2009, Cell stem cell.

[26]  M. Wicha,et al.  Phase Ib Pilot Study to Evaluate Reparixin in Combination with Weekly Paclitaxel in Patients with HER-2–Negative Metastatic Breast Cancer , 2017, Clinical Cancer Research.

[27]  A. Chang,et al.  Concise Reviews : Targeting Cancer Stem Cells Using Immunologic Approaches , 2015 .

[28]  Ash A. Alizadeh,et al.  Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. , 2010, JAMA.

[29]  P. Pelicci,et al.  Biological and Molecular Heterogeneity of Breast Cancers Correlates with Their Cancer Stem Cell Content , 2010, Cell.

[30]  J. Crowley,et al.  Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy. , 2015, Blood.

[31]  Michael D. Brooks,et al.  Therapeutic Implications of Cellular Heterogeneity and Plasticity in Breast Cancer. , 2015, Cell stem cell.

[32]  H. Kouji,et al.  A phase Ib dose-escalation study of PRI-724, a CBP/beta-catenin modulator, plus gemcitabine (GEM) in patients with advanced pancreatic adenocarcinoma (APC) as second-line therapy after FOLFIRINOX or FOLFOX. , 2015 .

[33]  Edward J. Kim,et al.  Pilot Clinical Trial of Hedgehog Pathway Inhibitor GDC-0449 (Vismodegib) in Combination with Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma , 2014, Clinical Cancer Research.

[34]  D. Pollyea,et al.  Therapeutic targeting of acute myeloid leukemia stem cells. , 2017, Blood.

[35]  N. McGranahan,et al.  The causes and consequences of genetic heterogeneity in cancer evolution , 2013, Nature.

[36]  R. Weinberg,et al.  How does multistep tumorigenesis really proceed? , 2015, Cancer discovery.

[37]  H. Mackay,et al.  A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia. , 2015, Gynecologic oncology.

[38]  A. Jimeno,et al.  A Phase I, Dose-Finding Study in Patients with Advanced Solid Malignancies of the Oral γ-Secretase Inhibitor PF-03084014 , 2014, Clinical Cancer Research.

[39]  Suzanne F. Jones,et al.  Phase 1/1b study of the FAK inhibitor defactinib (VS-6063) in combination with weekly paclitaxel for advanced ovarian cancer. , 2014 .

[40]  A. Maitra,et al.  A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma , 2014, Investigational New Drugs.

[41]  Robert A. Weinberg,et al.  Poised Chromatin at the ZEB1 Promoter Enables Breast Cancer Cell Plasticity and Enhances Tumorigenicity , 2013, Cell.

[42]  T. MacDonald,et al.  A Five-Gene Hedgehog Signature Developed as a Patient Preselection Tool for Hedgehog Inhibitor Therapy in Medulloblastoma , 2014, Clinical Cancer Research.

[43]  A. Krešo,et al.  Evolution of the cancer stem cell model. , 2014, Cell stem cell.

[44]  Carlo C. Maley,et al.  Clonal evolution in cancer , 2012, Nature.

[45]  Olivier Elemento,et al.  Stem Cell Lineage Infidelity Drives Wound Repair and Cancer , 2017, Cell.

[46]  M. Caligiuri,et al.  A cell initiating human acute myeloid leukaemia after transplantation into SCID mice , 1994, Nature.

[47]  Dong Wang,et al.  Breast Cancer Stem Cells Transition between Epithelial and Mesenchymal States Reflective of their Normal Counterparts , 2013, Stem cell reports.

[48]  A. Brandes,et al.  A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. , 2016, Neuro-oncology.

[49]  Angelo J. Canty,et al.  Stem cell gene expression programs influence clinical outcome in human leukemia , 2011, Nature Medicine.

[50]  R. Salgia,et al.  Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  Paolo Vineis,et al.  Prediction of acute myeloid leukaemia risk in healthy individuals , 2018, Nature.

[52]  Emanuela M. Ghia,et al.  Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia. , 2018, Cell stem cell.

[53]  R. Weinberg,et al.  Tackling the cancer stem cells — what challenges do they pose? , 2014, Nature Reviews Drug Discovery.

[54]  L. Dirix,et al.  An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[55]  Hans Clevers,et al.  The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. , 2011, Cell stem cell.

[56]  E. Passegué,et al.  Normal and leukemic stem cell niches: insights and therapeutic opportunities. , 2015, Cell stem cell.

[57]  Douglas Hanahan,et al.  Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment Prospects and Obstacles for Therapeutic Targeting of Function-enabling Stromal Cell Types , 2022 .

[58]  A. Letai,et al.  Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. , 2016, Cancer discovery.

[59]  John M. Ashton,et al.  Evolution of acute myelogenous leukemia stem cell properties after treatment and progression. , 2013, Blood.

[60]  Andreas H. Nuber,et al.  Long-lived intestinal tuft cells serve as colon cancer-initiating cells. , 2014, The Journal of clinical investigation.

[61]  A. D’Alessandro,et al.  Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells. , 2018, Cancer cell.

[62]  Claude Preudhomme,et al.  A 17-gene stemness score for rapid determination of risk in acute leukaemia , 2016, Nature.

[63]  Austin E. Gillen,et al.  Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia , 2018, Nature Medicine.

[64]  Ian Krop,et al.  Preclinical and Clinical Studies of Gamma Secretase Inhibitors with Docetaxel on Human Breast Tumors , 2013, Clinical Cancer Research.

[65]  J. Olson,et al.  Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  M. Todaro,et al.  Colorectal cancer stem cells: from the crypt to the clinic. , 2014, Cell stem cell.

[67]  R. Dummer,et al.  The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. , 2016, Journal of the American Academy of Dermatology.

[68]  Branimir Sikic,et al.  A Phase I Dose Escalation and Expansion Study of the Anticancer Stem Cell Agent Demcizumab (Anti-DLL4) in Patients with Previously Treated Solid Tumors , 2014, Clinical Cancer Research.

[69]  T. Tsuruo,et al.  Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  Yu Xia,et al.  Lipid Desaturation Is a Metabolic Marker and Therapeutic Target of Ovarian Cancer Stem Cells. , 2017, Cell stem cell.

[71]  D. Vetrie,et al.  The chronic myeloid leukemia stem cell: stemming the tide of persistence. , 2017, Blood.

[72]  P. Meltzer,et al.  Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis). , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  S. Skvortsov,et al.  Radiation resistance: Cancer stem cells (CSCs) and their enigmatic pro-survival signaling. , 2015, Seminars in cancer biology.

[74]  H. Johnsen,et al.  Cancer stem cell definitions and terminology: the devil is in the details , 2012, Nature Reviews Cancer.

[75]  A. Gilman,et al.  The initial clinical trial of nitrogen mustard. , 1963, American journal of surgery.

[76]  R. Levy,et al.  Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma , 2017, The New England journal of medicine.

[77]  E. Lam,et al.  Stem cell transcription factor NANOG controls cell migration and invasion via dysregulation of E-cadherin and FoxJ1 and contributes to adverse clinical outcome in ovarian cancers , 2013, Oncogene.

[78]  T. MacDonald,et al.  A phase I/II study of LDE225, a smoothened (Smo) antagonist, in pediatric patients with recurrent medulloblastoma (MB) or other solid tumors , 2012 .

[79]  J. Visvader,et al.  Cancer stem cells in solid tumours: accumulating evidence and unresolved questions , 2008, Nature Reviews Cancer.

[80]  Shawn M. Gillespie,et al.  Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance. , 2017, Cell stem cell.

[81]  R. Berger,et al.  A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours , 2014, British Journal of Cancer.

[82]  A. Oza,et al.  A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503) , 2012, British Journal of Cancer.

[83]  T. Beißbarth,et al.  Enrichment of CD133‐expressing cells in rectal cancers treated with preoperative radiochemotherapy is an independent marker for metastasis and survival , 2013, Cancer.

[84]  I. Weissman,et al.  Clonal Evolution of Preleukemic Hematopoietic Stem Cells Precedes Human Acute Myeloid Leukemia , 2012, Science Translational Medicine.

[85]  M. Prados,et al.  Targeting glioma-initiating cells in GBM: ABTC-0904, a randomized phase 0/II study targeting the Sonic Hedgehog-signaling pathway. , 2014 .

[86]  J. Rich,et al.  Cancer stem cells in glioblastoma , 2015, Genes & development.

[87]  M. Heuser,et al.  Modeling the functional heterogeneity of leukemia stem cells: role of STAT5 in leukemia stem cell self-renewal. , 2009, Blood.

[88]  Ben S. Wittner,et al.  A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations , 2010, Cell.

[89]  P. Nowell.  The clonal evolution of tumor cell populations. , 1976, Science.

[90]  A. Chang,et al.  Myeloid-Derived Suppressor Cells Endow Stem-like Qualities to Breast Cancer Cells through IL6/STAT3 and NO/NOTCH Cross-talk Signaling. , 2016, Cancer research.

[91]  M. Konopleva,et al.  Results from Phase 2 Trial Ongoing Expansion Stage of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) , 2016 .

[92]  D. Birnbaum,et al.  CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. , 2010, The Journal of clinical investigation.

[93]  J. Wolff,et al.  Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. , 1948, The New England journal of medicine.

[94]  N. McGranahan,et al.  Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future , 2017, Cell.

[95]  A 41-gene signature derived from breast cancer stem cells as a predictor of survival , 2014, Journal of experimental & clinical cancer research : CR.

[96]  Andrew P. Feinberg,et al.  An LSC epigenetic signature is largely mutation independent and implicates the HOXA cluster in AML pathogenesis , 2015, Nature Communications.

[97]  Jeffrey M. Rosen,et al.  Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features , 2009, Proceedings of the National Academy of Sciences.

[98]  F. Kuo,et al.  A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma , 2015, Blood Cancer Journal.

[99]  M. Zaaroor,et al.  Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study , 2010, Neuro-oncology.

[100]  Corbin E. Meacham,et al.  Tumour heterogeneity and cancer cell plasticity , 2013, Nature.

[101]  J. Blay,et al.  GDC-0449 in patients with advanced chondrosarcomas: a French Sarcoma Group/US and French National Cancer Institute Single-Arm Phase II Collaborative Study. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[102]  M. Berger,et al.  A phase I trial of the Hedgehog inhibitor, sonidegib (LDE225), in combination with etoposide and cisplatin for the initial treatment of extensive stage small cell lung cancer. , 2016, Lung cancer.

[103]  David C. Smith,et al.  A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors , 2017, Clinical Cancer Research.

[104]  J. Supko,et al.  A phase I extension study of BBI608, a first-in-class cancer stem cell (CSC) inhibitor, in patients with advanced solid tumors. , 2014 .

[105]  A. Behrens,et al.  Fbw7 and its counteracting forces in stem cells and cancer: Oncoproteins in the balance. , 2016, Seminars in cancer biology.

[106]  C. Compton,et al.  Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[107]  Jens-Peter Volkmer,et al.  The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors , 2012, Proceedings of the National Academy of Sciences.

[108]  A. Difeo,et al.  Cisplatin induces stemness in ovarian cancer , 2016, Oncotarget.

[109]  Z. Madjd,et al.  Clinical significance of putative cancer stem cell marker CD44 in different histological subtypes of lung cancer. , 2014, Cancer biomarkers : section A of Disease markers.

[110]  R. Vij,et al.  A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. , 2012, Blood.

[111]  Manuel Hidalgo,et al.  Tumor-initiating cells are rare in many human tumors. , 2010, Cell stem cell.

[112]  P. Murawa,et al.  The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial , 2010, International journal of cancer.

[113]  B. Karlan,et al.  A Phase II, Randomized, Placebo-Controlled Study of Vismodegib as Maintenance Therapy in Patients with Ovarian Cancer in Second or Third Complete Remission , 2012, Clinical Cancer Research.

[114]  G. Kristiansen,et al.  Accumulation of ALDH1-positive cells after neoadjuvant chemotherapy predicts treatment resistance and prognosticates poor outcome in ovarian cancer , 2015, Oncotarget.

[115]  W. Matsui.  Cancer stem cell signaling pathways , 2016, Medicine.

[116]  U. Olsson‐Strömberg,et al.  Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients , 2013, Leukemia.

[117]  Deric M. Park,et al.  Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma , 2016, Journal of Neuro-Oncology.

[118]  Q. Waisfisz,et al.  High Stem Cell Frequency in Acute Myeloid Leukemia at Diagnosis Predicts High Minimal Residual Disease and Poor Survival , 2005, Clinical Cancer Research.

[119]  Yang Liu,et al.  Targeting HIF1α eliminates cancer stem cells in hematological malignancies. , 2011, Cell stem cell.

[120]  H. Clevers,et al.  Intestinal Tumorigenesis Initiated by Dedifferentiation and Acquisition of Stem-Cell-like Properties , 2013, Cell.

[121]  John M. Ashton,et al.  BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. , 2013, Cell stem cell.

[122]  Robert Beckman,et al.  Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[123]  Y. Nakamura,et al.  Genetic alterations during colorectal-tumor development. , 1988, The New England journal of medicine.